+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating a new way to treat children aged 1 to 18 years with chronic kidney disease CKD and proteinuria, a condition where kidneys leak protein into the urine. The study focuses on adding finerenone to existing treatments of angiotensin-converting enzyme inhibitors ACEI or angiotensin receptor blockers ARB, which are commonly used to control blood pressure and protect kidney function. The goal is to understand the long-term safety of finerenone combined with these standard treatments, as well as its effect on kidney health and protein levels in urine. Participants will receive finerenone adjusted for age and body weight alongside their current ACEI or ARB therapy. The treatment period lasts up to 18 months, followed by one month of follow-up. During this time, patients will attend at least 12 visits if newly starting finerenone or at least 8 visits if continuing from a previous study, where various health measurements and tests will be conducted. Throughout the study, researchers will monitor participants blood pressure, heart rate, temperature, height, weight, and kidney function through blood and urine tests. They will also perform physical exams, heart checks using electrocardiograms and echocardiography, and collect information on medication use and any side effects. Safety is a primary focus, with careful tracking of any medical problems that arise during treatment, plus a health check about 30 days after the last dose. The entire participation lasts approximately 19 months.

Age: 1Year - 18YearsAll GendersPhase 3
151 locations
E

Actively Recruiting

Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.

Age: 18Years +All GendersPhase 3
279 locations
E

Actively Recruiting

This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.

Age: 18Years +All GendersPhase 3
473 locations
G

Actively Recruiting

This research evaluates a multifaceted intervention to improve lipid-lowering therapy among patients hospitalized for Type I myocardial infarction in the Asia-Pacific region. The study compares an early intervention group receiving the approach at baseline to a late intervention group initially receiving standard care. It is a multinational, randomized, parallel-group study aiming to enhance guideline-directed lipid management through patient and clinician engagement. The intervention involves a cholesterol score card used by both patients and their clinicians to document LDL cholesterol levels, adherence to therapy, management decisions, and current prescribed treatments. Risk stratification using the SMART Risk score and Lpa measurement is shared with both patients and their primary care clinicians. The late intervention group receives standard care for the first 6 months, including lipid profile reports to their doctor, before receiving the intervention at 6 months. Participants are involved for 12 months, with the first 6 months focusing on either early intervention or standard care, followed by crossover for the late group. Follow-up visits include updating the cholesterol score card at clinical appointments. Researchers measure the proportion of patients achieving LDL cholesterol below 1.4 mmolL at 6 and 12 months, therapy intensification, medication adherence, and patient activation. The study monitors outcomes through routine clinical care, aiming to reflect real-world practice.

Age: 18Years +All GendersPhase Not Applicable
22 locations
S

Actively Recruiting

Healthy Volunteer

This observational study focuses on determining how common nasopharyngeal carriage of Streptococcus pneumoniae is among Malaysian children aged 5 years and under. It aims to identify the types of pneumococcal bacteria present, their resistance to antibiotics, and how these factors relate to vaccination status and social factors. The study addresses a key health concern since pneumococcal carriage can lead to serious infections like pneumonia, which is a leading cause of death in young children in Malaysia. Participants include healthy and mildly symptomatic children from urban and semi-urban areas in Kuala Lumpur, Selangor, and Negeri Sembilan. Each child undergoes a single nasopharyngeal swab to detect the presence of pneumococcal bacteria. Researchers collect vaccination and demographic data through standardized forms with parental consent. Samples are analyzed using bacterial culture, antimicrobial susceptibility testing, and advanced whole-genome sequencing to identify bacterial types and resistance patterns. During the study, children are seen once for sample collection and data recording. The researchers measure the prevalence of pneumococcal carriage and analyze the genomic profiles of the bacteria over an 18-month period. This comprehensive approach helps understand how vaccination programs are influencing bacterial types and resistance in the community. The studys findings will support public health decisions on pneumococcal vaccination strategies in Malaysia.

Age: 0Years - 5YearsAll Genders
4 locations
S

Actively Recruiting

Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.

Age: 18Years +All GendersPhase 4
264 locations